Hemodialysis Membrane Biocompatibility - Does It Matter?

REFERENCES

• Schiffl H, Lang SM, König A, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344: 570–572.
   Google Scholar
• Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331: 1338–1342.
   Google Scholar
• Himmelfarb J, Tolkoff Rubin N, Chandran P, Parker RA, Wingard RL, Hakim R. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9: 257–266.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30: 366–373.
   Google Scholar
• McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialy-sers. Am J Kidney Dis 1997; 29: 576–583.
   PubMed Web of Science ®Google Scholar
• Caramelo C, Alcázar R, Gallar P. Teruel JL, Velo M, Ortega O, et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 675–677.
   Google Scholar
• Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophane. Kidney Int 1991; 40: 714–719.
   PubMed Web of Science ®Google Scholar
• Collins DM, Lambert MB, Tannenbaum JS, Oliverio M, Schwab SJ. Tolerance of hemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency hemodialysis. J Am Soc Nephrol 1993; 4: 148–154.
   Google Scholar
• Skroeder NR, Jacobson SH, Lins L-E, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration and biocompatibility of dialysis. Artif Organs 1994; 18: 880–887.
   Google Scholar
• Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross-sectional study. Kidney Int 1991; 39: 320–327.
   PubMed Web of Science ®Google Scholar
• Homberger JC, Chemew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admis-sions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227–1237.
   PubMed Web of Science ®Google Scholar
• van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J., and the Working Party on Dialysis Amyloidosis. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39: 1012–1019.
   PubMed Web of Science ®Google Scholar
• Hakim RM, Wingard RL, Husni L, Parker RA, Parker III PF. The effect of membrane biocompatibility on plasma 02-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7: 472–478.
   Google Scholar
• Coda Y, Nishi S, Miyazaki S, Haginoshita S, Sakur-abayashi T, Suzuki M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–1101.
   Google Scholar
• Gutierrez A, Alvestrand A, Wahren J, Bergstrom J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487–494.
   PubMed Web of Science ®Google Scholar
• Parker III TF, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompat-ibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996; 49: 551–556.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G. and the Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treat-ment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293–1302.
   Google Scholar
• Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420–425.
   Google Scholar
• Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 20: 361–366.
   Google Scholar
• Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3: 1409–1415.
   Google Scholar
• Ingram AJ, Parbtani A, Churchill DN. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins-a crossover trial. Nephrol Dial Transplant 1998; 13: 1452–1457.
   Google Scholar
• Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50: 550–556.
   PubMed Web of Science ®Google Scholar
• Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566–570.
   PubMed Web of Science ®Google Scholar
• Charra B, Calemard E, Ruffet M, Chazot C, Terrat J-C, Vanel T, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286–1291.
   PubMed Web of Science ®Google Scholar
• Buccianti G, Ravasi B, Cresseri D, Maisonneuve P. Boyle P, Locatelli F. Cancer in patients on renal replacement therapy in Lombardy, Italy. Lancet 1996; 347: 59–60.
   PubMed Web of Science ®Google Scholar
• NKF-DOQI clinical practical guidelines for hemodia-lysis adequacy. Am J Kidney Dis 1997; 30 (Suppl 2): S15–S66.
   Google Scholar